Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807485 | 0.92 | ITGB2 (0.41) | HSD11B1CALCRLCYP3A4TNKSPARP1 | |
| SCHEMBL6807459 | 0.91 | C5AR1 (0.41) | CALCRLCYP3A4DRD2DRD4DRD3 | |
| SCHEMBL6807473 | 0.91 | CALCRL (0.41) | CALCRLCYP3A4TNKSPARP1PARP2 | |
| SCHEMBL6808589 | 0.90 | CALCRL (0.52) | HSD11B1CALCRLCYP3A4DRD2DRD4 | |
| SCHEMBL6803451 | 0.87 | CALCRL (0.40) | HSD11B1CALCRLCYP3A4TNKSPARP1 | |
| SCHEMBL6807848 | 0.86 | TACR1 (0.40) | ECE1ITGB1ITGA4POLB | |
| SCHEMBL6808312 | 0.86 | HSD17B10 (0.42) | HSD11B1TNKSPARP1ECE1ITGB1 | |
| SCHEMBL6808899 | 0.85 | KMT2A (0.41) | ECE1ITGB1ITGA4 | |
| SCHEMBL6809212 | 0.85 | POLB (0.53) | ECE1POLB | |
| SCHEMBL6802705 | 0.85 | KMT2A (0.42) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | HSD11B1 3877/4885CALCRL 1811/4885CYP3A4 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.